## Francesco Rubino

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1715899/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Bariatric Surgery versus Conventional Medical Therapy for Type 2 Diabetes. New England Journal of Medicine, 2012, 366, 1577-1585.	27.0	1,617
2	Bariatric–metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet, The, 2015, 386, 964-973.	13.7	998
3	How Do We Define Cure of Diabetes?. Diabetes Care, 2009, 32, 2133-2135.	8.6	852
4	The Mechanism of Diabetes Control After Gastrointestinal Bypass Surgery Reveals a Role of the Proximal Small Intestine in the Pathophysiology of Type 2 Diabetes. Annals of Surgery, 2006, 244, 741-749.	4.2	782
5	Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations. Diabetes Care, 2016, 39, 861-877.	8.6	718
6	Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes and Endocrinology,the, 2020, 8, 546-550.	11.4	680
7	New-Onset Diabetes in Covid-19. New England Journal of Medicine, 2020, 383, 789-790.	27.0	624
8	Effect of Duodenal–Jejunal Exclusion in a Non-obese Animal Model of Type 2 Diabetes. Annals of Surgery, 2004, 239, 1-11.	4.2	581
9	The Early Effect of the Roux-en-Y Gastric Bypass on Hormones Involved in Body Weight Regulation and Glucose Metabolism. Annals of Surgery, 2004, 240, 236-242.	4.2	552
10	Joint international consensus statement for ending stigma of obesity. Nature Medicine, 2020, 26, 485-497.	30.7	468
11	Metabolic Surgery to Treat Type 2 Diabetes: Clinical Outcomes and Mechanisms of Action. Annual Review of Medicine, 2010, 61, 393-411.	12.2	350
12	Potential of Surgery for Curing Type 2 Diabetes Mellitus. Annals of Surgery, 2002, 236, 554-559.	4.2	315
13	The Diabetes Surgery Summit Consensus Conference. Annals of Surgery, 2010, 251, 399-405.	4.2	298
14	Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial. Lancet, The, 2021, 397, 293-304.	13.7	272
15	Is Type 2 Diabetes an Operable Intestinal Disease?. Diabetes Care, 2008, 31, S290-S296.	8.6	215
16	Duodenal-jejunal bypass for the treatment of type 2 diabetes in patients with body mass index of 22–34 kg/m2: a report of 2 cases. Surgery for Obesity and Related Diseases, 2007, 3, 195-197.	1.2	200
17	Endoscopic Duodenal Mucosal Resurfacing for the Treatment of Type 2 Diabetes: 6-Month Interim Analysis From the First-in-Human Proof-of-Concept Study. Diabetes Care, 2016, 39, 2254-2261.	8.6	171
18	COVID-19 and metabolic disease: mechanisms and clinical management. Lancet Diabetes and Endocrinology,the, 2021, 9, 786-798.	11.4	155

FRANCESCO RUBINO

#	Article	IF	CITATIONS
19	The utility of weight loss medications after bariatric surgery for weight regain or inadequate weight loss: A multi-center study. Surgery for Obesity and Related Diseases, 2017, 13, 491-500.	1.2	153
20	Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes. Diabetes Care, 2021, 44, 2438-2444.	8.6	152
21	Bariatric and metabolic surgery during and after the COVID-19 pandemic: DSS recommendations for management of surgical candidates and postoperative patients and prioritisation of access to surgery. Lancet Diabetes and Endocrinology,the, 2020, 8, 640-648.	11.4	139
22	Metabolic surgery for the treatment of type 2 diabetes in obese individuals. Diabetologia, 2018, 61, 257-264.	6.3	134
23	Metabolic Surgery. Journal of the American College of Cardiology, 2018, 71, 670-687.	2.8	130
24	Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations. Surgery for Obesity and Related Diseases, 2016, 12, 1144-1162.	1.2	126
25	Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: a Joint Statement by International Diabetes Organizations. Obesity Surgery, 2017, 27, 2-21.	2.1	118
26	Duodenal-jejunal bypass protects GK rats from β-cell loss and aggravation of hyperglycemia and increases enteroendocrine cells coexpressing GIP and GLP-1. American Journal of Physiology - Endocrinology and Metabolism, 2011, 300, E923-E932.	3.5	91
27	Insulin Sensitivity and Secretion Changes After Gastric Bypass in Normotolerant and Diabetic Obese Subjects. Annals of Surgery, 2013, 257, 462-468.	4.2	66
28	Bariatric, Metabolic, and Diabetes Surgery. Annals of Surgery, 2014, 259, 117-122.	4.2	65
29	Duodenal-Jejunal Bypass and Jejunectomy Improve Insulin Sensitivity in Goto-Kakizaki Diabetic Rats Without Changes in Incretins or Insulin Secretion. Diabetes, 2014, 63, 1069-1078.	0.6	51
30	Diabetes, obesity and <scp>COVID</scp> â€19: A complex interplay. Diabetes, Obesity and Metabolism, 2020, 22, 1892-1896.	4.4	51
31	IDF's view of bariatric surgery in type 2 diabetes. Lancet, The, 2011, 378, 108-110.	13.7	48
32	Surgical control of obesity and diabetes: The role of intestinal vs. gastric mechanisms in the regulation of body weight and glucose homeostasis. Obesity, 2014, 22, 159-169.	3.0	40
33	Consensus report: definition and interpretation of remission in type 2 diabetes. Diabetologia, 2021, 64, 2359-2366.	6.3	39
34	What is the Mechanism Behind Weight Loss Maintenance with Gastric Bypass?. Current Obesity Reports, 2015, 4, 262-268.	8.4	36
35	Short-term Effects of Laparoscopic Adjustable Gastric Banding Versus Roux-en-Y Gastric Bypass. Diabetes Care, 2016, 39, 1925-1931.	8.6	35
36	Identifying Barriers to Appropriate Use of Metabolic/Bariatric Surgery for Type 2 Diabetes Treatment: Policy Lab Results. Diabetes Care, 2016, 39, 954-963.	8.6	34

FRANCESCO RUBINO

#	Article	IF	CITATIONS
37	Is the Gut the "Sweet Spot―for the Treatment of Diabetes?. Diabetes, 2014, 63, 2225-2228.	0.6	33
38	Consequences of the COVID-19 pandemic for patients with metabolic diseases. Nature Metabolism, 2021, 3, 289-292.	11.9	33
39	From Bariatric to Metabolic Surgery: Definition of a New Discipline and Implications for Clinical Practice. Current Atherosclerosis Reports, 2013, 15, 369.	4.8	32
40	Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 1-9.	3.6	32
41	Obesity, Type 2 Diabetes, and the Metabolic Syndrome. Surgical Clinics of North America, 2016, 96, 681-701.	1.5	31
42	Metabolic surgery for treating type 2 diabetes mellitus: Now supported by the world's leading diabetes organizations. Cleveland Clinic Journal of Medicine, 2017, 84, S47-S56.	1.3	31
43	Knowledge gaps and weight stigma shape attitudes toward obesity. Lancet Diabetes and Endocrinology,the, 2020, 8, 363-365.	11.4	27
44	Medical research: Time to think differently about diabetes. Nature, 2016, 533, 459-461.	27.8	25
45	The coming of age of metabolic surgery. Nature Reviews Endocrinology, 2012, 8, 702-704.	9.6	24
46	Downregulation of Insulin Sensitivity After Oral Glucose Administration: Evidence for the Anti-Incretin Effect. Diabetes, 2017, 66, 2756-2763.	0.6	24
47	Male Obesity Associated Gonadal Dysfunction and the Role of Bariatric Surgery. Frontiers in Endocrinology, 2020, 11, 408.	3.5	19
48	Response to Comment on Rubino et al. Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations. Diabetes Care 2016;39:861–877. Diabetes Care, 2016, 39, e202-e203.	8.6	18
49	Roux-en-Y Gastric Bypass Surgery in the Management of Familial Partial Lipodystrophy Type 1. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3616-3620.	3.6	16
50	Will medications that mimic gut hormones or target their receptors eventually replace bariatric surgery?. Metabolism: Clinical and Experimental, 2019, 100, 153960.	3.4	16
51	Consensus report: Definition and interpretation of remission in type 2 diabetes. Diabetic Medicine, 2022, 39, e14669.	2.3	15
52	Management of diabetes in patients with COVID-19 – Authors' reply. Lancet Diabetes and Endocrinology,the, 2020, 8, 669-670.	11.4	14
53	The Effect of Standard Versus Longer Intestinal Bypass on GLP-1 Regulation and Clucose Metabolism in Patients With Type 2 Diabetes Undergoing Roux-en-Y Gastric Bypass: The Long-Limb Study. Diabetes Care, 2021, 44, 1082-1090.	8.6	14
54	Refractory Hyperglycemia After Gastric Bypass Surgery: A Novel Subtype of Type 2 Diabetes?. Diabetes Care, 2014, 37, e254-e255.	8.6	8

FRANCESCO RUBINO

#	Article	IF	CITATIONS
55	Long limb compared with standard limb Roux-en-Y gastric bypass for type 2 diabetes and obesity: the LONG LIMB RCT. Efficacy and Mechanism Evaluation, 2021, 8, 1-54.	0.7	7
56	Metabolic surgery: the cutting edge of diabetes care. Nature Reviews Gastroenterology and Hepatology, 2017, 14, 389-390.	17.8	5
57	Returning to Surgery—Experience, Discussions and Consensus. Obesity Surgery, 2021, 31, 1336-1338.	2.1	2
58	Obesity: what's in a word?. Lancet Diabetes and Endocrinology,the, 2021, 9, 408-409.	11.4	2
59	The effect of COVID-19 on routine diabetes care and mortality in people with diabetes. Lancet Diabetes and Endocrinology,the, 2022, 10, 550-551.	11.4	2
60	Bariatric and metabolic surgery during and after the COVID-19 pandemic – Authors' reply. Lancet Diabetes and Endocrinology,the, 2020, 8, 743-744.	11.4	1
61	Response to Comment on Gastaldelli et al. Short-term Effects of Laparoscopic Adjustable Gastric Banding Versus Roux-en-Y Gastric Bypass. Diabetes Care 2016;39:1925–1931. Diabetes Care, 2017, 40, e50-e50.	8.6	0
62	Diabetes Surgery. , 2015, , 81-97.		0

5